Atorvastatin Therapy on Xanthoma in Alagille Syndrome

Status Recruiting

Clinical Trial Summary

To observe the efficacy and safety of atorvastatin on xanthoma in Alagille syndrome through a prospective study.

Clinical Trial Description

Alagille syndrome (ALGS, OMIM 118450) is an important cause of chronic cholestasis in children, and the incidence rate is about 1:30000~1:50000. Most patients with ALGS have hypercholesterolemia. In severe cases, multiple xanthomas can be seen, and some patients are accompanied by severe itching and pain. Disfigured xanthomas affect the normal social interaction of patients, thereby causing physical and mental damage to children. At present, xanthoma caused by hypercholesterolemia can be cured by treating the primary disease, taking lipid-lowering drugs (such as bile acid chelators, ezetimibe, statins, etc.), or lipoprotein apheresis. If it affects the beauty or function, local treatment such as 33% trichloroacetic acid dot coating, carbon dioxide laser, liquid nitrogen freezing or surgical resection is feasible, and even surgical operation( such as portal vena cava anastomosis, liver transplantation). Compared with expensive lipoprotein apheresis and other invasive therapies, taking lipid-lowering drug has the advantages of higher acceptance, lower cost and higher safety. However, at present, there are no guidelines for application of oral lipid-lowering drugs in children under 6 years old with hypercholesterolemia. Therefore, the purpose of this study is to clarify the safety and efficacy of atorvastatin on xanthoma in ALGS , so as to provide reference for the treatment of ALGS patients' xanthomas. Risk prevention and treatment: The patients began to take atorvastatin from a small dose, followed up closely in the early stage (2-4 weeks) to see if the patients had obvious discomfort such as myalgia, and monitored the changes of Biochemistry (CK, ALT, AST, etc.). If moderate or more serious adverse reactions occurred during the trial or the following laboratory abnormalities occurred (CK exceeded 10 times the upper limit of normal; ALT or AST had been continued to rise, exceeding 2 times the baseline value), atorvastatin was temporarily stopped, and patients should be rechecked within 2 weeks. It is necessary to reevaluate and decide whether to restart atorvastatin treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05488067
Study type	Interventional
Source	Children's Hospital of Fudan University
Contact	Jianshe Wang, doctor
Phone	18017590987
Email	jshwang@shmu.edu.cn
Status	Recruiting
Phase	Phase 4
Start date	March 22, 2022
Completion date	March 22, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04729751` - A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).	Phase 2
Active, not recruiting	`NCT05035030` - Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome	Phase 3
Recruiting	`NCT06193928` - Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP)
Completed	`NCT02160782` - Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)	Phase 2
Completed	`NCT00007033` - Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease	N/A
Suspended	`NCT00571272` - Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Completed	`NCT02057692` - Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome	Phase 2
Active, not recruiting	`NCT02922751` - FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Completed	`NCT00001642` - Positional Cloning of the Gene(s) Responsible for Alagille Syndrome	N/A
Completed	`NCT04674761` - Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome	Phase 3
Completed	`NCT02117713` - An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome	Phase 2
Completed	`NCT02131623` - Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
Completed	`NCT02963077` - A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384	Phase 1
Recruiting	`NCT01793168` - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed	`NCT03082937` - An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects	Phase 1
Completed	`NCT02047318` - An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)	Phase 2
Completed	`NCT01903460` - Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome	Phase 2
Completed	`NCT01515631` - Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review
Enrolling by invitation	`NCT05846854` - Decreasing Hemorrhage Risk in Children With Alagille Syndrome	N/A
Approved for marketing	`NCT04530994` - A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)